GleamWall
中文EN

NGNE Neurogene Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1404644 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-40.0%
TTM EPS YoY-22.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-38.4%
ROA-35.8%
ROIC (approx.)-43.7%
Asset turnover—

Leverage & solvency

Liabilities / assets6.1%
Debt / equity0.00x
Current ratio19.97x
Interest coverage-129,924.00x

Cash quality & payout

Operating cash flow / net income0.81x
Accruals ratio-6.8%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue———$0$0$0—$0
R&D expense$23.52M$25.47M$25.15M$20.64M$17.24M$19.37M$17.76M$15.35M
SG&A expense$8.85M$11.20M$8.20M$6.89M$6.56M$6.71M$8.16M$6.17M
Operating income-$32.38M-$36.67M-$33.35M-$27.53M-$23.80M-$26.08M-$25.92M-$21.51M
Interest expense$0$0$0$1,000$1,000$1,000$2,000$2,000
Net income-$29.02M-$34.49M-$30.93M-$24.73M-$20.95M-$22.02M-$22.65M-$19.51M
EBITDA-$31.55M-$35.86M-$32.50M-$26.75M-$23.00M-$25.28M-$25.17M-$20.73M
EPS (basic)-1.05-1.53-1.39—-0.99-1.05-1.08—
EPS (diluted)-1.05-1.53-1.39—-0.99-1.05-1.08—
Weighted avg. shares (diluted)27.70M22.55M22.31M—21.17M21.06M21.00M—
Balance sheet
Cash & equivalents$78.94M$112.48M$124.16M$103.84M$71.34M$59.15M$71.11M$136.93M
Short-term investments$280.78M$112.91M$119.02M$165.17M$194.41M$215.71M$221.83M$175.82M
Current assets$362.74M$228.91M$246.75M$271.77M$270.52M$278.99M$296.40M$315.92M
PP&E, net$11.19M$11.73M$12.50M$12.79M$13.48M$14.25M$14.81M$15.42M
Total assets$377.90M$244.36M$263.14M$288.60M$287.83M$297.32M$315.30M$335.73M
Current liabilities$18.16M$21.50M$18.87M$16.41M$14.71M$15.44M$14.09M$15.16M
Total liabilities$23.11M$27.23M$25.36M$23.72M$22.29M$24.06M$23.51M$25.36M
Shareholders' equity$354.79M$217.13M$237.78M$264.89M$265.54M$273.25M$291.80M$310.38M
Shares outstanding20.69M15.83M15.62M15.49M14.78M14.27M14.93M14.85M
Cash flow statement
Operating cash flow-$29.14M-$23.76M-$26.12M-$17.43M-$19.51M-$19.46M-$20.77M-$17.50M
Capital expenditure$315,000$354,000$281,000$128,000$127,000$148,000$780,000$116,000
Free cash flow-$29.46M-$24.11M-$26.40M-$17.56M-$19.64M-$19.61M-$21.55M-$17.61M
Investing cash flow-$165.99M$6.10M$46.24M$29.61M$21.99M$7.45M-$45.05M-$102.62M
Financing cash flow$161.60M$5.98M$195,000$20.66M$9.71M$54,000$4,000$190.06M
Depreciation & amortization$821,000$813,000$847,000$776,000$800,000$800,000$749,000$785,000
Stock-based compensation$5.15M$7.86M$3.63M$3.36M$3.37M$3.41M$4.05M$2.49M

Free plan shows the latest 8 periods; Pro shows all 55 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.